Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

Catriona Jamieson, Robert Hasserjian, Jason Gotlib, Jorge Cortes, Richard Stone, Moshe Talpaz, Jürgen Thiele, Scott Rodig, Olga Pozdnyakova

Research output: Contribution to journalArticle

Abstract

Background: Progressive bone marrow fibrosis (BMF) is a cardinal feature of many myeloproliferative neoplasms (MPNs) and there is a documented association between the severity of BMF and overall prognosis. We conducted an exploratory analysis of sequential BMF data from two phase I studies of long-term treatment with the Janus kinase 2 (JAK2) inhibitor fedratinib in patients with myelofibrosis. Methods: Bone marrow samples were obtained at baseline and after every six cycles (24weeks) of daily fedratinib treatment. Fibrosis was centrally assessed by three independent haematopathologists, who were blinded to the patients' data, and graded according to European Consensus Myelofibrosis Grading Criteria. The analysis population comprised patients with a baseline BMF grade ≥1, and at least one post-baseline BMF grade assessment. Changes in BMF grade compared with baseline were classified as improvement (≥1 grade reduction), stabilisation (no change in any baseline BMF grade <3) or worsening (≥1 grade increase). Results: Twenty-one patients were included in the analysis. A total of 153 bone marrow samples were analysed. Improvement or stabilisation of BMF from baseline was recorded in 15 of 18 (83%) evaluable patients at cycle 6 and in four of nine (44%) evaluable patients at cycle 30. Two patients achieved resolution of their BMF (grade=0) by cycle 12. Conclusions: This exploratory analysis indicates that improvement or even resolution of BMF may be achievable with JAK2 inhibitor therapy in some patients with MPNs and myelofibrosis.

Original languageEnglish (US)
Article number294
JournalJournal of Translational Medicine
Volume13
Issue number1
DOIs
StatePublished - Sep 10 2015
Externally publishedYes

Fingerprint

Janus Kinase 2
Primary Myelofibrosis
Bone
Therapeutics
TG101348
Stabilization
Bone Marrow

Keywords

  • Fibrosis
  • Janus kinase inhibitor
  • Myelofibrosis
  • Myeloproliferative neoplasms
  • Philadelphia chromosome-negative

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. / Jamieson, Catriona; Hasserjian, Robert; Gotlib, Jason; Cortes, Jorge; Stone, Richard; Talpaz, Moshe; Thiele, Jürgen; Rodig, Scott; Pozdnyakova, Olga.

In: Journal of Translational Medicine, Vol. 13, No. 1, 294, 10.09.2015.

Research output: Contribution to journalArticle

Jamieson, Catriona ; Hasserjian, Robert ; Gotlib, Jason ; Cortes, Jorge ; Stone, Richard ; Talpaz, Moshe ; Thiele, Jürgen ; Rodig, Scott ; Pozdnyakova, Olga. / Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. In: Journal of Translational Medicine. 2015 ; Vol. 13, No. 1.
@article{6dee8429ab9c4d049608e428409434b2,
title = "Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis",
abstract = "Background: Progressive bone marrow fibrosis (BMF) is a cardinal feature of many myeloproliferative neoplasms (MPNs) and there is a documented association between the severity of BMF and overall prognosis. We conducted an exploratory analysis of sequential BMF data from two phase I studies of long-term treatment with the Janus kinase 2 (JAK2) inhibitor fedratinib in patients with myelofibrosis. Methods: Bone marrow samples were obtained at baseline and after every six cycles (24weeks) of daily fedratinib treatment. Fibrosis was centrally assessed by three independent haematopathologists, who were blinded to the patients' data, and graded according to European Consensus Myelofibrosis Grading Criteria. The analysis population comprised patients with a baseline BMF grade ≥1, and at least one post-baseline BMF grade assessment. Changes in BMF grade compared with baseline were classified as improvement (≥1 grade reduction), stabilisation (no change in any baseline BMF grade <3) or worsening (≥1 grade increase). Results: Twenty-one patients were included in the analysis. A total of 153 bone marrow samples were analysed. Improvement or stabilisation of BMF from baseline was recorded in 15 of 18 (83{\%}) evaluable patients at cycle 6 and in four of nine (44{\%}) evaluable patients at cycle 30. Two patients achieved resolution of their BMF (grade=0) by cycle 12. Conclusions: This exploratory analysis indicates that improvement or even resolution of BMF may be achievable with JAK2 inhibitor therapy in some patients with MPNs and myelofibrosis.",
keywords = "Fibrosis, Janus kinase inhibitor, Myelofibrosis, Myeloproliferative neoplasms, Philadelphia chromosome-negative",
author = "Catriona Jamieson and Robert Hasserjian and Jason Gotlib and Jorge Cortes and Richard Stone and Moshe Talpaz and J{\"u}rgen Thiele and Scott Rodig and Olga Pozdnyakova",
year = "2015",
month = "9",
day = "10",
doi = "10.1186/s12967-015-0644-4",
language = "English (US)",
volume = "13",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

AU - Jamieson, Catriona

AU - Hasserjian, Robert

AU - Gotlib, Jason

AU - Cortes, Jorge

AU - Stone, Richard

AU - Talpaz, Moshe

AU - Thiele, Jürgen

AU - Rodig, Scott

AU - Pozdnyakova, Olga

PY - 2015/9/10

Y1 - 2015/9/10

N2 - Background: Progressive bone marrow fibrosis (BMF) is a cardinal feature of many myeloproliferative neoplasms (MPNs) and there is a documented association between the severity of BMF and overall prognosis. We conducted an exploratory analysis of sequential BMF data from two phase I studies of long-term treatment with the Janus kinase 2 (JAK2) inhibitor fedratinib in patients with myelofibrosis. Methods: Bone marrow samples were obtained at baseline and after every six cycles (24weeks) of daily fedratinib treatment. Fibrosis was centrally assessed by three independent haematopathologists, who were blinded to the patients' data, and graded according to European Consensus Myelofibrosis Grading Criteria. The analysis population comprised patients with a baseline BMF grade ≥1, and at least one post-baseline BMF grade assessment. Changes in BMF grade compared with baseline were classified as improvement (≥1 grade reduction), stabilisation (no change in any baseline BMF grade <3) or worsening (≥1 grade increase). Results: Twenty-one patients were included in the analysis. A total of 153 bone marrow samples were analysed. Improvement or stabilisation of BMF from baseline was recorded in 15 of 18 (83%) evaluable patients at cycle 6 and in four of nine (44%) evaluable patients at cycle 30. Two patients achieved resolution of their BMF (grade=0) by cycle 12. Conclusions: This exploratory analysis indicates that improvement or even resolution of BMF may be achievable with JAK2 inhibitor therapy in some patients with MPNs and myelofibrosis.

AB - Background: Progressive bone marrow fibrosis (BMF) is a cardinal feature of many myeloproliferative neoplasms (MPNs) and there is a documented association between the severity of BMF and overall prognosis. We conducted an exploratory analysis of sequential BMF data from two phase I studies of long-term treatment with the Janus kinase 2 (JAK2) inhibitor fedratinib in patients with myelofibrosis. Methods: Bone marrow samples were obtained at baseline and after every six cycles (24weeks) of daily fedratinib treatment. Fibrosis was centrally assessed by three independent haematopathologists, who were blinded to the patients' data, and graded according to European Consensus Myelofibrosis Grading Criteria. The analysis population comprised patients with a baseline BMF grade ≥1, and at least one post-baseline BMF grade assessment. Changes in BMF grade compared with baseline were classified as improvement (≥1 grade reduction), stabilisation (no change in any baseline BMF grade <3) or worsening (≥1 grade increase). Results: Twenty-one patients were included in the analysis. A total of 153 bone marrow samples were analysed. Improvement or stabilisation of BMF from baseline was recorded in 15 of 18 (83%) evaluable patients at cycle 6 and in four of nine (44%) evaluable patients at cycle 30. Two patients achieved resolution of their BMF (grade=0) by cycle 12. Conclusions: This exploratory analysis indicates that improvement or even resolution of BMF may be achievable with JAK2 inhibitor therapy in some patients with MPNs and myelofibrosis.

KW - Fibrosis

KW - Janus kinase inhibitor

KW - Myelofibrosis

KW - Myeloproliferative neoplasms

KW - Philadelphia chromosome-negative

UR - http://www.scopus.com/inward/record.url?scp=84941206924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941206924&partnerID=8YFLogxK

U2 - 10.1186/s12967-015-0644-4

DO - 10.1186/s12967-015-0644-4

M3 - Article

C2 - 26357842

AN - SCOPUS:84941206924

VL - 13

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 294

ER -